CN103734560A - Method for removal of reactive carbonyl compounds in high fructose corn syrup (HFCS) - Google Patents
Method for removal of reactive carbonyl compounds in high fructose corn syrup (HFCS) Download PDFInfo
- Publication number
- CN103734560A CN103734560A CN201310642428.1A CN201310642428A CN103734560A CN 103734560 A CN103734560 A CN 103734560A CN 201310642428 A CN201310642428 A CN 201310642428A CN 103734560 A CN103734560 A CN 103734560A
- Authority
- CN
- China
- Prior art keywords
- hfcs
- final concentration
- carbonyl compound
- active carbonyl
- interpolation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000019534 high fructose corn syrup Nutrition 0.000 title claims abstract description 81
- 150000001728 carbonyl compounds Chemical class 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 40
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 20
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 20
- 239000011718 vitamin C Substances 0.000 claims abstract description 20
- 235000014620 theaflavin Nutrition 0.000 claims abstract description 18
- 230000008569 process Effects 0.000 claims abstract description 14
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims abstract description 12
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 6
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims abstract description 5
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000010376 calcium ascorbate Nutrition 0.000 claims abstract description 5
- 229940047036 calcium ascorbate Drugs 0.000 claims abstract description 5
- 239000011692 calcium ascorbate Substances 0.000 claims abstract description 5
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims abstract description 5
- 229940068041 phytic acid Drugs 0.000 claims abstract description 5
- 235000002949 phytic acid Nutrition 0.000 claims abstract description 5
- 239000000467 phytic acid Substances 0.000 claims abstract description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 5
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 5
- 235000010378 sodium ascorbate Nutrition 0.000 claims abstract description 5
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims abstract description 5
- 229960005055 sodium ascorbate Drugs 0.000 claims abstract description 5
- 235000010265 sodium sulphite Nutrition 0.000 claims abstract description 5
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 229940001482 sodium sulfite Drugs 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 19
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims description 17
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims description 17
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims description 17
- 229940026509 theaflavin Drugs 0.000 claims description 17
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 10
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 10
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 10
- 235000010350 erythorbic acid Nutrition 0.000 claims description 8
- -1 D-araboascorbic acid sodium salt Chemical class 0.000 claims description 4
- 235000013616 tea Nutrition 0.000 claims description 4
- DINKXUCRJBUQAZ-UHFFFAOYSA-N tert-butyl 5-bromopyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CN=CC(Br)=C1 DINKXUCRJBUQAZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000012545 processing Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 abstract 1
- 244000269722 Thea sinensis Species 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 16
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 15
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical class CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 239000005715 Fructose Substances 0.000 description 9
- 229930091371 Fructose Natural products 0.000 description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 9
- 229940015043 glyoxal Drugs 0.000 description 8
- OXFWZSUJNURRMW-NTSWFWBYSA-N 3-deoxy-keto-D-fructose Chemical compound OC[C@@H](O)[C@@H](O)CC(=O)CO OXFWZSUJNURRMW-NTSWFWBYSA-N 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 6
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 5
- 238000001212 derivatisation Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091008606 PDGF receptors Proteins 0.000 description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 108700040099 Xylose isomerases Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000004705 aldimines Chemical class 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- VTYFITADLSVOAS-NSHDSACASA-N 1-(L-norleucin-6-yl)pyrraline Chemical compound OC(=O)[C@@H](N)CCCCN1C(CO)=CC=C1C=O VTYFITADLSVOAS-NSHDSACASA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- XCYPSOHOIAZISD-MLWJPKLSSA-N N(6)-(1-carboxyethyl)-L-lysine Chemical compound OC(=O)C(C)NCCCC[C@H](N)C(O)=O XCYPSOHOIAZISD-MLWJPKLSSA-N 0.000 description 1
- NUXSIDPKKIEIMI-LURJTMIESA-N N(6)-carboxymethyl-L-lysine Chemical compound OC(=O)[C@@H](N)CCCCNCC(O)=O NUXSIDPKKIEIMI-LURJTMIESA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention provides a method for removal of reactive carbonyl compounds in high fructose corn syrup (HFCS). The technical proposal adopted by the method is as follows: in a HFCS production processing process or a production processing process using the HFCS as a raw material, adding a clearing factor, fully mixing, under the condition of 30-40 DEG C, mixing, and reacting for 1 to 4 hours. The clearing factor use amount is 0.01%-0.5% of the HFCS mass, and the clearing factor is at least one from vitamin C, sodium hydrosulfite, ethylenediamine tetraacetic acid disodium, theaflavins, tea polyphenols, sodium sulfite, phytic acid, sodium ascorbate, calcium ascorbate, D-Isoascorbic acid or D-isoascorbic acid sodium salt. The method can effectively remove the reactive carbonyl compounds in the high fructose corn syrup, and has the advantages of simple procedure and high removal rate of the reactive carbonyl compounds, and the maximum removal rate is up to above 60%.
Description
Technical field
The present invention relates to the removal of active carbonyl compound in HFCS in field of food.
Background technology
HFCS (hereinafter to be referred as HFCS), claiming again high fructose syrup or isomery syrup, is the isomerization through glucose isomerase with the saccharified liquid of enzyme process starch saccharification gained, and wherein a part of glucose isomerase becomes fructose, take the mixing molasses that fructose and glucose forms as key component, HFCS has many-sided peculiar property, as the Synergistic of sugariness, and cold sweet and tasty mouthful of property, high-dissolvability and hyperosmosis, hygroscopicity, moisture retention and anti-crystallization, superior Fermented and processing and storage stability etc.At present increasingly extensive in the application of food processing field as the substitute of sucrose.
The glucide such as glucose, fructose oxidation reaction can produce a series of compound as 3-deoxyfructose (3-Dexoyglucosone, 3-DOG), glyoxal (Glyoxal, GO), methyl-glyoxals (Methylglyoxal, MGO) etc., are referred to as active carbonyl compound.Active carbonyl compound belongs to the glycosylation factor of high reaction, higher 200～50000 times than the activity of glucose.Under normal physiological conditions, activity in vivo carbonyl compound concentration is lower 10000～50000 times than glucose, but still is the important as precursors that generates advanced glycation end products (advanced glycation end products, AGEs).Active carbonyl compound is a kind of reactive metabolic intermediate, resulting from nonenzymatic glycosylation reaction, sugared degradation process and metabolic disease etc., is a kind of high response toxic chemical, has carcinogenicity, cytotoxicity and the quick biological natures such as AGEs that generate, participate in the development of many chronic diseases.There are some researches show under diabetic disease states, blood plasma MGO level significantly raises, and MGO level is relevant with controlling degree of blood sugar.When the people's such as Paul J.Beisswenger research shows diabetic with fast-developing ephrosis complication, the level of MGO raises.This phenomenon has all obtained confirmation in the In vitroandin vivotrial of type 1 diabetes and diabetes B.In addition the people's such as HoweU.S research is also found under diabetic disease states, and 3-DOG level raises, and in renal tissue, 3-DOG level and diabetic nephropathy have significant correlation.The experiment in vitro such as Cantero show that the Enrichment of GO and MGO causes platelet-derived growth factor receptors (PDGFR) distortion and mitogenesis Functional change, and in the mouse atherosclerotic lesions of diabetes apo E disappearance, also find identical PDGFR distortion, show that GO and MGO may make also to have occurred in body identical dysfunction.
Advanced glycation end products (AGEs) is the end-product of non-enzymatic glycation, under the condition without enzyme, the glucose molecule free aldehyde of open chain or ketone group and gal4 amino acid residue side chain epsilon-amino or aminoterminal alpha-amido are by affine combination, generate rapidly aldimine (aldimine), be Schiff alkali, this is a unsettled intermediate product.Unsettled Schiff base reaches balance in vivo very soon, subsequently, can slowly there is molecular structure chemical rearrangement in Schiff base, form more stable but still be reversible sugar-protein ketoamine bond, this kind of alkaline product is more stable, and the invertibity of reaction lowers greatly, through rearranging, form the more stable 1-amino-1-deoxidation-D-ketose (1-amino-1-deoxy-D-ketose) of character, i.e. Amadori product, this commitment that is glycosylation.Amadori product or Amadori product are through the reactive carbonyls of multiple height of multistep dehydration and molecular rearrangement generation, as 3-deoxyfructose, glyoxal, methyl-glyoxal etc., further react with other free amine groups, finally form the AGEs of irreversibility, this is the late stage of glycosylation.AGEs is the general name of the material of many different structures, now known as CML, CEL, Pentosidine, Pyrraline, crossline etc.Researcher thinks that AGEs is the sign that protein is aging at first, so that in body, identification is degraded, remove aging protein.Along with to the deep discovery of AGEs research, it is not only relevant with adorned macromolecular degraded, AGEs and its acceptor interaction, can activate a plurality of signal transduction pathways, promote the synthetic of cytokine profiles and discharge, by mechanism such as injured blood vessel endothelium, promotion leukocyte, increase platelet aggregation and stimulation vascular smooth muscle cell proliferations, promote generation and the development of the chronic complicating diseases of diabetes such as atherosclerotic, diabetic vascular complications, uremia.Advanced glycation end products is not only relevant with diabetic complication, it also can cause the connection of iuntercellular molecule, cause the irreversible abnormal change of extracellular matrix protein, the albumen that AGEs modifies is by stimulating body to produce cell factor and oxygen radical with the special receptors bind of AGEs, the AGEs while is the interior albumen of modified cells also, cause protein function abnormal, cause eventually the pathology of connective tissue, crystalline lens, blood vessel and nerve etc.
In requiring for HFCS physics and chemistry in the production GB of HFCS, only there is solid content, glucose, fructose content, pH, colourity, insoluble particulates, sulfated ass, these requirements of transmittance, do not have the relevant regulations about active carbonyl compound content.Due to active carbonyl compound extensive use in food production to the potential toxic action of human body and HFCS, thereby be necessary for the research of how to remove active carbonyl compound.
Summary of the invention
The object of the invention is to, a kind of method of removing active carbonyl compound in HFCS is provided.By pending HFCS sample is contacted with removing molecule, under 30 ℃ of-40 ℃ of conditions, react, thus the content of active carbonyl compound in minimizing sample.
In order to achieve the above object, the technical solution used in the present invention is:
A method of removing active carbonyl compound in HFCS, comprises the steps:
In HFCS, add clearing factor, after fully mixing, under 30-40 ℃ of condition, mix, reaction 1-4 hour, the consumption of clearing factor is 0.1 ‰～5% of HFCS quality.
The interpolation time of described clearing factor is in HFCS process of manufacture or take in the process of manufacture that HFCS is raw material.
Described clearing factor is vitamin C, sodium dithionite, at least one in disodium ethylene diamine tetraacetate, theaflavin, Tea Polyphenols, sodium sulfite, phytic acid, sodium ascorbate, Calcium Ascorbate, D-araboascorbic acid or D-araboascorbic acid sodium salt.
Described ascorbic final concentration scope is 0.1mg/mL～0.8mg/mL.
The final concentration scope of described sodium dithionite is 50mg/mL～100mg/mL.
The final concentration scope of described disodium ethylene diamine tetraacetate is 50mg/mL～150mg/mL.
The final concentration scope of described theaflavin is 1mg/mL～10mg/mL.
The final concentration scope of described Tea Polyphenols is 1mg/mL～6mg/mL.
The final concentration scope of described sodium sulfite is 50mg/mL～150mg/mL.
The final concentration scope of described phytic acid is 0.05mg/mL～0.15mg/mL.
The final concentration scope of described sodium ascorbate is 0.3mg/mL～0.8mg/mL.
The final concentration scope of described Calcium Ascorbate is 0.2mg/mL～0.7mg/mL.
The final concentration scope of described D-araboascorbic acid is 1mg/mL～4mg/mL.
The final concentration scope of described D-araboascorbic acid sodium salt is 2mg/mL～5mg/mL.
Beneficial effect:
Thereby 1, realized a kind of HFCS is reacted at 30 ℃-40 ℃ with clearing factor enough time effectively remove HFCS in the method for active carbonyl compound.Because these clearing factors are non-oxidizability food additives, under 30 ℃ of-40 ℃ of reaction conditions, can effectively remove the active carbonyl compound in HFCS, there is operation simple, the advantage that active carbonyl compound clearance is high.
2, the clearance of active carbonyl compound, because of the removing molecular species of use and the difference of active carbonyl compound kind difference, reaches as high as more than 60%.
3, this invention is applicable in HFCS process of manufacture, or take HFCS among raw material process of manufacture.
Accompanying drawing explanation:
Fig. 1 is active carbonyl compound content chromatogram in blank HFCS
Fig. 2 is active carbonyl compound content chromatogram partial enlarged drawing in blank HFCS
Fig. 3 is vitamin C effect active carbonyl compound content chromatogram in HFCS after three hours
Fig. 4 is sodium dithionite effect active carbonyl compound content chromatogram in HFCS after a hour
Fig. 5 is theaflavin effect active carbonyl compound content chromatogram in HFCS after three hours.
The specific embodiment
Below by specific embodiment, the invention will be further described, and following examples are descriptive, is not determinate, can not limit protection scope of the present invention with this.
Embodiment 1: the removal of vitamin C to active carbonyl compound in HFCS
Measure HFCS (55% fructose, 42% glucose) 1L(and be about 1.25kg), adding final concentration is that the vitamin C of 0.2mg/mL is placed in reaction vessel and fully mixes, and is placed on 30 ℃ of constant temperature, under 80rpm condition, reacts.The HFCS sample after 1mL processes is got in reaction after 3h, in 1/1(v/v) ratio to add concentration be 0.1%(w/v) o-phenylenediamine solution, 60 ℃ of water-bath lucifuges derive 30min.After derivatization reaction, cross film and carry out HPLC analysis.Not add ascorbic HFCS sample to contrast.Chromatographic condition is: chromatographic column: Agilent ZORBAX SB-C18 post (5 μ m, 4.6 * 250mm); Mobile phase is: A:0.15%(v/v) acetic acid aqueous solution-B: methyl alcohol, adopts gradient elution; Column temperature: 25 ℃; Flow velocity: 0.7mL/min; Wavelength: 313nm; Sample size is 20 μ L, carries out chromatography, records chromatogram (Fig. 1,2,3).Gradient elution program is as table one.
Table one: gradient elution program
| Time(min) | A(%) | B(%) |
| 0 | 92 | 8 |
| 10 | 70 | 30 |
| 20 | 30 | 70 |
| 30 | 100 | 0 |
| 40 | 92 | 8 |
The content of active carbonyl compound is as shown in table two, three:
Table two: active carbonyl compound content in blank HFCS
| GO(μg/gHFCS) | MGO(μg/gHFCS) | 3-DOG(μg/gHFCS) |
| 365 | 237.50 | 86625 |
Table three: active carbonyl compound content in HFCS after vitamin C effect 3h
| GO(μg/gHFCS) | MGO(μg/gHFCS) | 3-DOG(μg/gHFCS) |
| nd | nd | 24861.40 |
Calculate after vitamin C and HFCS effect 3h, the clearance of active carbonyl compound is: the clearance of 3-deoxyfructose: 71.30%; The clearance of glyoxal and methyl-glyoxal is: 100%.
Embodiment 2: the removal of sodium dithionite to active carbonyl compound in HFCS
Measure HFCS (42% fructose, 55% glucose) 1L(and be about 1.25kg) to add final concentration be the sodium dithionite of 56mg/mL, and be placed on 37 ℃ of constant temperature, under 80rpm condition, react.The HFCS sample after 1mL processes is got in reaction after 1h, in 1/1(v/v) ratio to add concentration be 0.1%(w/v) o-phenylenediamine solution, 60 ℃ of water-baths derive 30min.After derivatization reaction, cross film and carry out HPLC analysis.Not add the HFCS sample of sodium dithionite to contrast.Liquid phase testing conditions is with embodiment 1, and it is Fig. 1 that liquid phase detects figure, and 2,4.Result is as shown in table four, five.
Table four: active carbonyl compound content in blank HFCS
| GO(μg/gHFCS) | MGO(μg/gHFCS) | 3-DOG(μg/gHFCS) |
| 365 | 237.50 | 86625 |
Table five: active carbonyl compound content in HFCS after sodium dithionite effect 1h
| GO(μg/gHFCS) | MGO(μg/gHFCS) | 3-DOG(μg/gHFCS) |
| 1.46 | 44.18 | 28499.60 |
Calculate after sodium dithionite and HFCS effect 1h, the clearance of active carbonyl compound is: 3-deoxyfructose clearance: 67.10%; The clearance of glyoxal: 99.60%; The clearance of methyl-glyoxal is: 81.40%.
Embodiment 3: the removal of theaflavin to active carbonyl compound in HFCS
Measure HFCS (55% fructose, 42% glucose) 2L(and be about 2.5kg) be placed in reaction vessel, adding final concentration is that the theaflavin of 1.4mg/mL fully mixes and is placed on 40 ℃ of constant temperature, under 100rpm condition, reacts.The HFCS sample after 1mL processes is got in reaction after 3h, in 1/1(v/v) ratio to add concentration be 0.1%(w/v) o-phenylenediamine solution, 60 ℃ of water-baths derive 30min.After derivatization reaction, cross film and carry out HPLC analysis.Not add the HFCS sample of theaflavin to contrast.Liquid phase testing conditions is with embodiment 1, and it is Fig. 1 that liquid phase detects figure, and 2,5.Result is as shown in table six, seven.
Table six: active carbonyl compound content in blank HFCS
| GO(μg/gHFCS) | MGO(μg/gHFCS) | 3-DOG(μg/gHFCS) |
| 737 | 473 | 173250 |
Table seven: active carbonyl compound content in HFCS after theaflavin effect 3h
| GO(μg/gHFCS) | MGO(μg/gHFCS) | 3-DOG(μg/gHFCS) |
| nd | nd | 143624.25 |
Calculate after theaflavin and HFCS effect 3h, the clearance of active carbonyl compound is: the clearance of 3-deoxyfructose: 17.10%; The clearance of glyoxal: 100%; The clearance of methyl-glyoxal is: 100%.
Embodiment 4: vitamin C and theaflavin acting in conjunction are for active carbonyl compound in HFCS
Remove
Measure HFCS (42% fructose, 55% glucose) 1L(and be about 1.25kg) to add final concentration be the vitamin C of 0.2mg/mL and the theaflavin that final concentration is 1mg/mL, fully mixes and be placed on 37 ℃ of constant temperature in reaction vessel, under 80rpm condition, react.The HFCS sample after 1mL processes is got in reaction after 2h, in 1/1(v/v) ratio to add concentration be 0.1%(w/v) o-phenylenediamine solution, 60 ℃ of water-baths derive 30min.After derivatization reaction, cross film and carry out HPLC analysis.Not add the HFCS sample of vitamin C and theaflavin to contrast.Liquid phase testing conditions is with embodiment 1.Result is as shown in table eight, nine.
Table eight: active carbonyl compound content in blank HFCS
| GO(μg/gHFCS) | MGO(μg/gHFCS) | 3-DOG(μg/gHFCS) |
| 365 | 237.50 | 86625 |
Table nine: active carbonyl compound content in HFCS after vitamin C and theaflavin acting in conjunction
| GO(μg/gHFCS) | MGO(μg/gHFCS) | 3-DOG(μg/gHFCS) |
| nd | nd | 4331.25 |
Calculate after the common and HFCS effect 2h of vitamin C and theaflavin, the clearance of active carbonyl compound is: the clearance of 3-deoxyfructose: 95%; The clearance of glyoxal and methyl-glyoxal is: 100%.
Embodiment 5: disodium ethylene diamine tetraacetate and vitamin C acting in conjunction are for the removal of active carbonyl compound in HFCS
Measure HFCS (42% fructose, 55% glucose) 1L(and be about 1.25kg) to add final concentration be that final concentration is the disodium ethylene diamine tetraacetate of 50mg/mL and the vitamin C of 0.1mg/mL, after fully mixing in reaction vessel, be placed in 30 ℃ of constant temperature, under 80rpm condition, react.The HFCS sample after 1mL processes is got in reaction after 1h, in 1/1(v/v) ratio to add concentration be 0.1%(w/v) o-phenylenediamine solution, 60 ℃ of water-baths derive 30min.After derivatization reaction, cross film and carry out HPLC analysis.Not add disodium ethylene diamine tetraacetate and ascorbic HFCS sample to contrast.Liquid phase testing conditions is with embodiment 1.Result is as shown in table ten, 11.
Table ten: active carbonyl compound content in blank HFCS
| GO(μg/gHFCS) | MGO(μg/gHFCS) | 3-DOG(μg/gHFCS) |
| 365 | 237.50 | 86625 |
Table ten one: active carbonyl compound content in HFCS after vitamin C and disodium ethylene diamine tetraacetate acting in conjunction
| GO(μg/gHFCS) | MGO(μg/gHFCS) | 3-DOG(μg/gHFCS) |
| nd | nd | 17325 |
Calculate after the common and HFCS effect 1h of vitamin C and disodium ethylene diamine tetraacetate, the clearance of active carbonyl compound is: the clearance of 3-deoxyfructose: 80%; The clearance of glyoxal and methyl-glyoxal is: 100%.
Claims (9)
1. a method of removing active carbonyl compound in HFCS, is characterized in that, adds clearing factor in HFCS, after fully mixing, under 30-40 ℃ of condition, mix, reaction 1-4 hour, the consumption of clearing factor is 0.1 ‰～5% of HFCS quality.
2. a kind of method of removing active carbonyl compound in HFCS as claimed in claim 1, is characterized in that, the interpolation time of described clearing factor is in HFCS process of manufacture or take in the process of manufacture that HFCS is raw material.
3. a kind of method of removing active carbonyl compound in HFCS as claimed in claim 1 or 2, it is characterized in that, described clearing factor is at least one in vitamin C, sodium dithionite, disodium ethylene diamine tetraacetate, theaflavin, Tea Polyphenols, sodium sulfite, phytic acid, sodium ascorbate, Calcium Ascorbate, D-araboascorbic acid or D-araboascorbic acid sodium salt.
4. a kind of method of removing active carbonyl compound in HFCS as claimed in claim 1 or 2, is characterized in that, described ascorbic interpolation final concentration is 0.1mg/mL～0.8mg/mL; The interpolation final concentration of described sodium dithionite is 50mg/mL～100mg/mL; The interpolation final concentration of described disodium ethylene diamine tetraacetate is 50mg/mL～150mg/mL; The interpolation final concentration of described theaflavin is 1mg/mL～10mg/mL; The interpolation final concentration of described Tea Polyphenols is 1mg/mL～6mg/mL; The interpolation final concentration of described sodium sulfite is 50mg/mL～150mg/mL; The interpolation final concentration of described phytic acid is 0.05mg/mL～0.15mg/mL; The interpolation final concentration of described sodium ascorbate is 0.3mg/mL～0.8mg/mL; The interpolation final concentration of described Calcium Ascorbate is 0.2mg/mL～0.7mg/mL; The interpolation final concentration of described D-araboascorbic acid is 1mg/mL～4mg/mL; The interpolation final concentration of described D-araboascorbic acid sodium salt is 2mg/mL～5mg/mL.
5. a kind of method of removing active carbonyl compound in HFCS as claimed in claim 1 or 2, is characterized in that, described clearing factor is vitamin C, and interpolation final concentration is 0.2mg/mL.
6. a kind of method of removing active carbonyl compound in HFCS as claimed in claim 1 or 2, is characterized in that, described clearing factor is sodium dithionite, and interpolation final concentration is 56mg/mL.
7. a kind of method of removing active carbonyl compound in HFCS as claimed in claim 1 or 2, is characterized in that, described clearing factor is theaflavin, and interpolation final concentration is 1.4mg/mL.
8. a kind of method of removing active carbonyl compound in HFCS as claimed in claim 1 or 2, is characterized in that, described clearing factor is vitamin C and theaflavin, and final concentration is respectively 0.2mg/mL and 1mg/mL.
9. a kind of method of removing active carbonyl compound in HFCS as claimed in claim 1 or 2, is characterized in that, described clearing factor is disodium ethylene diamine tetraacetate and vitamin C, and final concentration is respectively 50mg/mL and 0.1mg/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310642428.1A CN103734560A (en) | 2013-12-02 | 2013-12-02 | Method for removal of reactive carbonyl compounds in high fructose corn syrup (HFCS) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310642428.1A CN103734560A (en) | 2013-12-02 | 2013-12-02 | Method for removal of reactive carbonyl compounds in high fructose corn syrup (HFCS) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103734560A true CN103734560A (en) | 2014-04-23 |
Family
ID=50491697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310642428.1A Pending CN103734560A (en) | 2013-12-02 | 2013-12-02 | Method for removal of reactive carbonyl compounds in high fructose corn syrup (HFCS) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103734560A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105541692A (en) * | 2015-12-18 | 2016-05-04 | 湖南益阳益威生化试剂有限公司 | Bilirubin stabilizer and bilirubin refining method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080138481A1 (en) * | 2006-12-07 | 2008-06-12 | Chi-Tang Ho | Methods of reducing reactive carbonyl species |
| CN103304657A (en) * | 2012-03-16 | 2013-09-18 | 东北林业大学 | Glycosylated modifying method for improving antioxidant activity of whey protein |
| CN103387612A (en) * | 2013-06-25 | 2013-11-13 | 南昌大学 | Rapid glycosylation method for modifying egg white protein |
-
2013
- 2013-12-02 CN CN201310642428.1A patent/CN103734560A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080138481A1 (en) * | 2006-12-07 | 2008-06-12 | Chi-Tang Ho | Methods of reducing reactive carbonyl species |
| CN103304657A (en) * | 2012-03-16 | 2013-09-18 | 东北林业大学 | Glycosylated modifying method for improving antioxidant activity of whey protein |
| CN103387612A (en) * | 2013-06-25 | 2013-11-13 | 南昌大学 | Rapid glycosylation method for modifying egg white protein |
Non-Patent Citations (8)
| Title |
|---|
| 叶晓蕾: "果葡糖浆中异味化合物的形成机理及其影响因素研究", 《现代农业科技》 * |
| 徐玮等: "《食品化学实验和习题》", 31 May 2008 * |
| 段振华: "《高级食品化学》", 31 January 2012 * |
| 田荣华: "亚硫酸盐在果葡糖浆生产中的作用", 《江苏食品与发酵》 * |
| 谢渝湘等: "羰基毒害在糖尿病晚期并发症中的作用", 《生命科学研究》 * |
| 贾曼等: "基于果糖自氧化体系的抗氧化剂筛选方法", 《高等学校化学学报》 * |
| 贾曼等: "糖自氧化及抗氧化剂对其抑制作用的研究进展", 《化学通报》 * |
| 钱萍萍等: "维生素C和维生素E对糖尿病大鼠非酶糖化和过氧化反应的影响", 《卫生研究》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105541692A (en) * | 2015-12-18 | 2016-05-04 | 湖南益阳益威生化试剂有限公司 | Bilirubin stabilizer and bilirubin refining method |
| CN105541692B (en) * | 2015-12-18 | 2018-03-02 | 湖南益旺生物科技有限公司 | Bilirubin stabilizer and bilirubin process for purification |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tian et al. | Bioactive flavonoids from Rubus corchorifolius inhibit α-glucosidase and α-amylase to improve postprandial hyperglycemia | |
| Alves et al. | Solubility of D-glucose in water and ethanol/water mixtures | |
| JP5996668B2 (en) | Active small molecule glue mixture, preparation method and use thereof | |
| Chen et al. | Preparation, deproteinization, characterisation, and antioxidant activity of polysaccharide from cucumber (Cucumis saticus L.) | |
| CN101985644B (en) | Momordica charantia polypeptide, preparation method and application thereof | |
| CN101301023A (en) | Pilose antler deer penis collagen polypeptide, and preparation and produced oral preparation thereof | |
| CN112641729B (en) | High-water-solubility chlortetracycline hydrochloride soluble powder and preparation method thereof | |
| CN104904950A (en) | Organic selenium-rich and chromium-rich blood-sugar-reducing tea and preparation method thereof | |
| Islam et al. | The inhibitory activities of the edible green alga Capsosiphon fulvescens on rat lens aldose reductase and advanced glycation end products formation | |
| CN111870659A (en) | Application of enzymolysis cereal bran extract in preparation of DPP-4 inhibitor | |
| CN103156879A (en) | Agent for suppressing elevation of blood alcohol concentration and method for suppressing elevation of blood alcohol concentration | |
| Wang et al. | Thinning of cluster improves berry composition and sugar accumulation in Syrah grapes | |
| WO2024041525A1 (en) | Composition, preparation method therefor, and use thereof | |
| CN103734560A (en) | Method for removal of reactive carbonyl compounds in high fructose corn syrup (HFCS) | |
| CN102172293B (en) | Corn active small peptide sober-up agent | |
| Fan et al. | Nutritional composition and α-glucosidase inhibitory activity of five Chinese vinegars | |
| CN103995079B (en) | The quantitative detecting method of content beta-carotene in beta carotene extract | |
| CN104473159A (en) | Actinidia polygama effervescing agent and preparation method and application thereof | |
| CN103409487A (en) | Method used for extracting maize germ active components | |
| CN103131592A (en) | Method for producing olive wine by using olive fruit juice through fermentation | |
| JP2007131599A6 (en) | Plant extract having glycation-inhibiting ability and method for producing the same | |
| JP2007131599A (en) | Plant extract containing glycation-inhibiting ability and method for producing the same | |
| AU2021101429A4 (en) | Method for extracting flavonoids as active substances from honey | |
| CN113100320B (en) | Walnut oligopeptide candy with function of relieving sub-health fatigue and preparation method thereof | |
| CN107674902A (en) | A kind of hunchbacked blood polypeptide with function of blood sugar reduction and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140423 |